StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
July 26, 2024 12:18 PM
Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $342.00 price target on Biogen (NASDAQ: BIIB)The analyst comments "The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Biogen (BIIB) PT Lowered to $294 at Baird
July 29, 2024 6:56 AM
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
July 26, 2024 10:40 AM
Biogen (BIIB) PT Lowered to $282 at RBC Capital
July 26, 2024 10:10 AM
Midday movers: Bristol-Myers, 3M and Deckers rise; Dexcom falls
July 26, 2024 7:47 AM
Biogen (BIIB): EMA has adopted a negative opinion on MAA of Lecanemab for early Alzheimer’s disease
July 26, 2024 7:22 AM
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024 7:20 AM
SAGE Therapeutics (SAGE) Falls 24% After Phase 2 KINETIC 2 Study of SAGE-324 Fails
July 24, 2024 7:43 AM
SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Topline Results from Phase 2 KINETIC 2 Study of SAGE-324
July 24, 2024 6:32 AM
Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor
July 24, 2024 6:30 AM
